Pieris Pharmaceuticals, Inc.

11.49 USD
+2.53 (+28.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Pieris Pharmaceuticals, Inc. stock is up 9.53% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 June’s closed higher than May.

About Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.